Xiaoaiping Injection Combined with Chemotherapy Versus Chemotherapy Alone for Breast Cancer: A Systematic Review and Meta-Analysis.

J Vis ExpOct 1, 2026 (epub)
Clinical ResearchOncology (Medical)

Zhao Yue, Wu Bo, Wang Yue-Kun et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the efficacy and safety of Xiaoaiping Injection (XAP) combined with chemotherapy versus chemotherapy alone in breast cancer patients. The analysis included eight studies and found that XAP significantly improved outcomes, with a reduction in chemotherapy-induced adverse effects and an increased objective response rate. The relative risk for adverse effects was 0.67.

Key findings

  • Xiaoaiping Injection combined with chemotherapy reduced the incidence of chemotherapy-induced adverse effects (RR = 0.67).
  • The objective response rate was significantly higher with XAP plus chemotherapy (RR = 1.37).
  • Pooled analysis showed significant improvement in patient outcomes with XAP (P < 0.05).

Why it matters

The findings suggest that incorporating Xiaoaiping Injection into chemotherapy regimens may enhance treatment efficacy and reduce adverse effects in breast cancer patients, which is crucial for improving patient quality of life and treatment adherence.

Source

PubMed · PMID 42825487

Published in J Vis Exp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.